use
immun
complex
ic
vaccin
long
histori
earli
anim
vaccin
foot
mouth
diseas
viru
mixtur
viru
antigen
immun
sera
develop
follow
observ
passiv
transfer
immun
serum
would
provid
short
window
immun
use
serum
mix
live
viru
provid
long
last
immun
lombard
et
al
even
today
principl
continu
use
new
anim
vaccin
develop
provid
stronger
immun
respons
standard
dose
vaccin
antigen
overcom
infect
remain
attenu
viru
prepar
overcom
exist
immun
exampl
matern
immun
haddad
et
al
jeurissen
et
al
man
use
ic
shown
benefici
treatment
chronic
infect
hepat
b
patient
hepat
b
surfac
antigen
complex
immunoglobulin
suffici
boost
immun
wen
et
al
immun
complex
also
shown
overcom
problem
preexist
immun
limit
therapeut
use
adenoviru
express
vector
purpos
gener
adenovirusantibodi
complex
target
immun
process
cell
prefer
normal
target
coxsacki
adenoviru
receptor
car
bear
cell
leopold
et
al
case
format
immun
complex
incub
antigen
antibodi
effect
decor
antigen
crystalliz
fragment
fc
immunoglobulin
heavi
chain
therebi
enabl
interact
fc
receptor
fcr
present
antigen
present
cell
apc
dendrit
cell
dc
target
way
antigen
effici
taken
process
apc
subsequ
adapt
immun
respons
acceler
intensifi
fig
major
histocompat
process
pathway
major
histocompat
complex
mhc
class
mhc
class
ii
activ
apc
rel
split
activ
associ
broadli
process
either
endogen
eg
viru
exogen
eg
bacteria
antigen
also
recogn
variou
pattern
recognit
receptor
prr
within
process
cell
gener
endogen
antigen
process
mhc
class
pathway
activ
cell
exogen
antigen
process
mhc
class
ii
activ
cell
howev
process
pathway
coexist
apc
exogen
antigen
also
cross
present
mhc
class
especi
capabl
bind
fcr
dc
regnault
et
al
deliveri
antigen
apc
particularli
dc
via
ic
therefor
effect
one
stop
shop
effici
present
immun
system
irrespect
natur
immunogen
capabl
stimul
respons
fold
compar
antigen
alon
kunkl
klau
et
al
obregon
et
al
valu
immun
target
apc
strength
longev
immun
respons
obtain
variou
differ
method
use
mimic
ic
format
addit
direct
mix
antigen
antibodi
influenza
vaccin
develop
exampl
inactiv
viru
treat
galactosyltransferas
vitro
add
epitop
glycosyl
influenza
protein
abdelmot
et
al
human
carri
natur
high
level
anti
antibodi
immun
modifi
glycoprotein
lead
opsonis
vaccin
antibodi
increas
immunogen
follow
interact
fc
portion
fcr
apc
abdelmot
et
al
wherea
random
endocytosi
uncomplex
antigen
apc
lead
poor
intern
consequ
low
immunogen
ic
mediat
entri
target
apc
cell
surfac
receptor
effect
initi
immun
respons
abdelmot
et
al
recombin
ic
also
construct
novel
concept
chargelegu
et
al
fuse
sequenc
fragment
tetanu
toxin
cterminu
heavi
chain
monoclon
antibodi
specif
antigen
overal
construct
express
transgen
tobacco
plant
found
fold
function
antibodi
complementar
determin
region
cdr
one
molecul
recogn
tetanu
tag
anoth
lead
format
complex
purifi
highli
immunogen
chargelegu
et
al
applic
similar
techniqu
larger
number
target
also
discuss
paul
et
al
conceptu
similar
vaccin
also
report
streptococcu
pneumonia
fusion
made
pneumococc
surfac
protein
singl
chain
antibodi
whose
cdr
specif
target
human
fcr
vaccin
concept
test
mice
transgen
use
fusion
protein
gave
higher
level
reactiv
immunoglobulin
serum
bronchoalveolar
lavag
fluid
compar
nonfus
surfac
protein
result
higher
level
protect
pneumonia
challeng
bitsaktsi
et
al
antigenfc
fusion
protein
take
concept
genet
fusion
antigen
fc
effector
domain
stage
remov
requir
cdr
complet
directli
conjug
fc
domain
antigen
fig
number
advantag
least
remov
requir
avail
preexist
antibodi
provid
simpl
manufactur
process
antigenfc
complex
purifi
homogen
affin
chromatographi
protein
protein
g
matric
uncertainti
ic
format
need
purifi
discret
size
class
complex
order
remov
excess
antigen
antibodi
therefor
avoid
virtu
singl
disulfid
bond
fc
monom
recombin
protein
pass
secretori
system
express
cell
becom
disulfid
link
dimer
offer
potenti
cross
link
fcr
bind
even
antigen
concern
natur
monomer
result
advantag
number
fc
fusion
protein
express
character
candid
vaccin
abdelmot
et
al
chen
et
al
konduru
et
al
pleass
zaharato
et
al
strategi
also
extens
investig
gener
cancer
vaccin
format
antigenantibodi
complex
use
tumor
marker
lead
fc
receptor
mediat
uptak
apc
stimul
cell
respons
abl
delay
tumor
growth
durrant
et
al
metheringham
et
al
enabl
gener
solut
addit
fctag
varieti
candid
antigen
rapid
clone
express
cassett
develop
base
exist
high
throughput
express
strategi
exampl
base
baculoviru
express
pengelley
et
al
transfer
vector
design
primarili
baculoviru
express
system
although
also
capabl
express
escherichia
coli
mammalian
cell
combin
strong
express
promot
well
express
cleav
signal
peptid
univers
multipl
clone
site
base
restrict
enzym
sfii
ctermin
fctag
provid
sequenc
human
fc
domain
fig
note
glycosyl
fcdomain
essenti
fcr
bind
thu
product
function
protein
requir
express
eucaryot
cell
jefferi
almost
code
sequenc
gener
polymeras
chain
reaction
includ
differenti
sfii
site
end
upon
clone
necessari
adjust
read
frame
univers
vector
result
secret
protein
tag
cterminu
human
fc
baculoviru
infect
insect
cell
experi
also
use
produc
parallel
express
vector
multipl
clone
region
append
terminu
sequenc
encod
transmembran
tm
domain
vesicular
stomat
viru
vsv
g
protein
origin
tag
import
vsv
gtm
well
character
sever
antibodi
avail
commerci
fragment
clone
vector
result
product
target
protein
instead
secret
display
plasma
membran
baculoviru
infect
cell
fig
use
vector
combin
allow
product
target
protein
solubl
fctag
molecul
purifi
infect
cell
supernat
nonfc
tag
equival
attach
infect
insect
cell
surfac
togeth
recombin
protein
target
express
use
pair
vector
allow
purif
target
homogen
gener
target
specif
serum
abil
detect
seroconvers
target
antigen
flow
cytometri
enzymelink
immunosorb
assay
elisa
cell
express
vsv
gtm
tag
form
protein
previou
antigen
specif
serum
requir
methodolog
express
fctag
vsv
gtm
tag
form
target
confirm
use
commerci
sourc
antibodi
date
strategi
employ
larg
number
viral
glycoprotein
proven
wide
applic
list
publish
unpublish
exampl
author
laboratori
shown
tabl
focus
use
baculoviru
express
system
product
candid
vaccin
materi
result
advantag
attribut
includ
high
throughput
high
express
level
protein
test
correct
posttransl
modif
lack
microbi
mammalian
pyrogen
endotoxin
hu
et
al
addit
shown
recent
direct
headtohead
comparison
protein
human
immunodefici
viru
hiv
envelop
protein
express
mammalian
insect
cell
immunogen
insect
deriv
glycoprotein
somewhat
higher
equival
materi
mammalian
cell
result
insect
cell
glycosyl
gener
appear
benefit
antibodi
gener
kong
et
al
baculoviru
express
technolog
matur
number
product
alreadi
marketplac
mani
pipelin
van
oer
king
baculoviru
express
system
appli
product
influenza
vaccin
exampl
prove
valuabl
facil
season
pandem
vaccin
treanor
tripp
tompkin
need
improv
hiv
envelop
vaccin
wide
discuss
walker
burton
final
matur
form
envelop
glycoprotein
compos
two
polypeptid
chain
respons
bind
primari
secondari
receptor
use
viru
cell
entri
respons
fusion
viral
host
cell
membran
fenouillet
et
al
initi
receptor
bind
step
enabl
predomin
target
gener
neutral
antibodi
compet
receptor
bind
prevent
viru
entri
pantophlet
burton
antibodi
shown
capabl
neutral
mani
hiv
clade
vitro
binley
et
al
vivo
baba
et
al
kitabwalla
et
al
recent
work
suggest
strongli
receptor
block
monoclon
antibodi
mab
abil
prevent
infect
simianhuman
immunodefici
viru
shiv
challeng
anim
model
weak
nonneutr
mab
essenti
ineffect
burton
et
al
polyclon
human
sera
function
similar
class
respons
bival
recombin
use
candid
vaccin
either
weak
present
pitisuttithum
et
al
plausibl
consequ
variou
immun
evas
mechan
use
hiv
glycan
shroud
sensit
site
wei
et
al
profus
sequenc
variat
catasti
et
al
structur
heterogen
moor
et
al
yuan
et
al
number
attempt
made
design
novel
immunogen
aim
elicit
wide
neutral
immun
respons
wildtyp
molecul
exampl
includ
purpos
engin
glycan
site
li
et
al
forc
immun
focu
domain
zollapazn
et
al
use
stabil
envelop
trimer
beddow
et
al
kang
et
al
forc
vitro
evolut
du
et
al
approach
gener
improv
envelop
immunogen
includ
improv
neutral
respons
singl
candid
yet
emerg
domin
list
vaccin
candid
routin
induc
strong
cross
clade
neutral
antibodi
respons
part
problem
hiv
natur
poorli
immunogen
addit
antibodi
produc
often
nonneutr
surfac
inner
domain
inner
domain
part
three
defin
structur
domain
inner
domain
bridg
sheet
outer
domain
od
rearrang
somewhat
upon
bind
chen
et
al
inner
domain
bridg
sheet
sourc
heterogen
within
monomer
solut
yuan
et
al
thu
gener
immun
less
mobil
domain
od
could
part
immun
focus
strategi
gener
stronger
cross
reactiv
immun
potenti
clear
epitop
broad
rang
neutral
human
mab
map
od
sander
et
al
scanlan
et
al
number
lectin
potent
neutral
viru
infect
vitro
also
bind
od
balzarini
et
al
howev
od
heavili
glycosyl
immunolog
silent
make
immun
isol
domain
challeng
use
sequenc
od
bc
recombin
clade
origin
isol
china
rodenburg
et
al
su
et
al
investig
fc
tag
could
enabl
immun
respons
sequenc
encod
od
residu
amplifi
clone
fc
vector
describ
cf
fig
recombin
baculovirus
gener
establish
method
pengelley
et
al
zhao
et
al
odfc
purifi
infect
cell
supernat
combin
chromatographi
lectin
len
culnari
sepharos
protein
sepharos
former
use
gener
way
enrich
glycoprotein
express
insect
cell
virtu
fact
highli
mannosyl
mammalian
glycoprotein
present
contamin
serum
addit
media
sialyl
therefor
pass
column
protein
captur
step
provid
essenti
purif
homogen
level
contamin
insect
cell
protein
extrem
low
appar
fctag
full
length
also
express
purifi
two
od
variat
also
construct
variant
remov
immunodomin
loop
sequenc
replac
loop
wellknown
cross
reactiv
neutral
epitop
deriv
membran
proxim
region
law
et
al
nontag
od
provid
suitabl
control
purifi
fusion
protein
migrat
singl
band
kda
sdspage
migrat
kda
consist
addit
fc
domain
kda
sequenc
use
case
fig
signific
cleavag
od
format
unlik
describ
previous
od
yang
et
al
gel
electrophoresi
use
sampl
buffer
nonreduc
agent
demonstr
protein
dimer
expect
fusion
fc
domain
antibodi
molecul
made
discret
domain
littl
reason
suppos
fusion
fc
domain
would
impact
fold
outer
domain
antigen
sequenc
clone
vector
formal
confirm
elisa
antibodi
react
linear
conform
epitop
show
tag
nontag
form
react
equival
inde
found
obviou
effect
overal
fold
follow
fc
tag
molecul
list
tabl
except
epitop
known
locat
close
fusion
junction
assess
potenti
immunogen
tag
nontag
protein
use
per
dose
immun
group
mice
adjuv
use
immun
sera
obtain
pool
assay
elisa
titer
purifi
alon
absenc
adjuv
poorli
immunogen
even
repeat
immun
howev
odfc
fusion
protein
elicit
signific
titer
provid
higher
titer
expect
larger
antigen
potenti
epitop
fig
addit
gener
serum
despit
delet
major
immunogen
determin
notabl
serum
gener
react
recombin
protein
contain
epitop
demonstr
outer
domain
act
scaffold
epitop
data
confirm
fc
tag
effect
solut
overcom
poor
immunogen
benefici
strategi
even
extrem
poor
immunogen
od
domain
experi
abrog
fcfcr
interact
mutagenesi
contact
site
within
fc
domain
lead
loss
immunogen
demonstr
target
apc
via
interact
fcr
mechan
immun
enhanc
expect
chen
et
al
result
posit
immun
respons
od
fragment
immun
strategi
use
odfc
absenc
adjuv
use
gener
panel
mab
highli
conserv
structur
domain
six
mab
domain
identifi
screen
odfc
nonrel
fctag
molecul
mab
use
probe
varieti
hiv
reveal
fine
select
demonstr
serum
specif
immun
sequenc
three
mab
react
strongli
tag
nontag
od
subsequ
epitop
map
neutral
test
show
two
mab
specif
loop
strongli
neutral
hiv
viru
carri
envelop
protein
chen
et
al
thu
tag
gener
broad
respons
epitop
across
target
sequenc
includ
epitop
direct
relev
vaccin
design
use
fc
domain
way
gone
unnot
human
fc
directli
fuse
hiv
candid
vaccin
target
also
shown
promis
result
qi
et
al
use
peptid
mimet
hairpin
fusion
intermedi
induc
cross
reactiv
antibodi
follow
coupl
peptid
human
fc
immun
mice
qi
et
al
notabl
neither
free
peptid
peptid
oligomer
addit
foldon
sequenc
deriv
bacteriophag
fibritin
alon
induc
substanti
antibodi
respons
cross
reactiv
neutral
antibodi
rais
also
gener
rabbit
fusion
protein
use
immunogen
zhang
et
al
suggest
studi
fc
domain
benefit
longev
immunogen
follow
immun
facilit
factor
respons
observ
gagfc
fusion
protein
shown
gener
mucos
immun
use
nasal
immun
lu
et
al
immun
demonstr
site
distal
site
immun
studi
explor
mechan
immun
enhanc
mice
detail
compar
variou
subclass
fc
effect
fc
domain
murin
found
superior
fc
domain
murin
three
differ
immunogen
test
two
hiv
one
influenza
viru
zaharato
et
al
murin
mous
equival
human
use
studi
od
describ
molecul
interact
mous
receptor
pleass
data
therefor
confirm
earlier
observ
knockout
mice
primari
mechan
antibodi
mediat
enhanc
immun
interact
receptor
wernersson
et
al
unlik
situat
hiv
success
vaccin
yet
develop
influenza
vaccin
clinic
use
mani
year
problem
case
gener
immun
per
se
rather
rapid
drift
viru
within
popul
requir
regular
vaccin
updat
rapid
method
vaccin
gener
addit
fear
pandem
outbreak
brought
fore
concern
around
vaccin
stockpil
antigen
spare
use
lower
amount
immunogen
enabl
dose
rapid
genetovaccin
approach
influenza
vaccin
use
fctag
could
make
contribut
concern
hemagglutinin
ha
glycoprotein
respons
influenza
viru
entri
host
cell
via
sialicacid
receptor
bind
activ
result
major
target
neutral
antibodi
cross
et
al
nicholson
et
al
skehel
wiley
success
influenza
vaccin
abl
elicit
neutral
antibodi
block
ha
sialic
acid
bind
consequ
prevent
spread
viru
popul
first
step
feasibl
studi
therefor
fc
tag
investig
gener
solut
make
rang
influenza
immunogen
absenc
ad
adjuv
full
length
extern
glycoprotein
sequenc
ha
amplifi
clone
baculoviru
transfer
vector
express
secret
fctag
ha
cell
surfac
bound
vsv
gtmtag
ha
ten
differ
express
use
format
tabl
result
effici
secret
fctag
protein
could
purifi
insect
cell
supernat
combin
lectin
protein
affin
chromatographi
alreadi
describ
test
red
blood
cell
bind
flow
cytometri
tag
protein
shown
function
fold
estim
size
solut
show
oligomer
predominantli
hexam
presum
driven
dimer
potenti
fc
domain
trimer
associ
full
length
ha
fig
purifi
hafc
protein
exampl
shown
ha
use
immun
balbc
mice
absenc
adjuv
case
dose
escal
studi
carri
order
assess
minimum
dose
requir
effici
seroconvers
antigen
candid
vaccin
evalu
postimmun
sera
elisa
use
havsvgtm
fusion
protein
captur
elisa
plate
surfac
layer
snowdrop
lectin
galanthu
nivali
lectin
gna
seroconvers
appar
dose
test
titer
respons
correl
dose
immunogen
fig
experi
littl
ng
hafc
absenc
addit
adjuv
result
seroconvers
extrapol
dose
use
man
use
formula
base
bodi
surfac
area
reaganshaw
et
al
base
dose
ng
gave
appreci
titer
adult
human
weight
kg
mous
weight
g
human
equival
dose
would
less
minimum
dose
shown
seroconvert
trial
baculoviru
express
nontag
ha
treanor
et
al
evid
therefor
hafc
fusion
protein
potent
immunogen
moreov
strategi
work
equal
well
rang
suggest
univers
applic
loureiro
et
al
mechan
immun
enhanc
shown
case
hiv
immunogen
via
fcfcr
interact
zaharato
et
al
success
vaccin
strategi
influenza
would
worthless
gener
inappropri
antibodi
respons
two
set
data
suggest
case
use
hafc
fusion
protein
respons
gener
relev
firstli
isotyp
serum
respons
immun
shown
predomin
profil
expect
previou
studi
solubl
recombin
ha
immunogen
treanor
et
al
main
antibodi
isotyp
produc
follow
antibodi
fig
helper
th
respons
contribut
typic
immun
respons
recombin
ha
vaccin
weldon
et
al
use
kappa
light
chain
also
domin
serum
respons
appreci
induct
iga
igm
overal
titer
subclass
fell
reduc
dose
immunogen
evid
differ
pattern
respons
level
immunogen
reduc
secondli
serum
gener
abl
prevent
ha
bind
red
blood
cell
fig
importantli
abl
reduc
viru
entri
suscept
cell
incub
pseudotyp
viru
use
homolog
ha
envelop
protein
loureiro
et
al
show
despit
alter
structur
ha
part
hafc
fusion
protein
antibodi
relev
neutral
viru
receptor
bind
domain
rbd
ha
gener
part
polyval
respons
similar
respons
gener
human
avian
serotyp
detail
epitop
map
use
peptid
array
confirm
predomin
respons
alway
gener
rbd
locat
top
subunit
although
antibodi
direct
domain
addit
express
domain
alon
fc
fusion
protein
gener
high
titer
serotyp
specif
antibodi
cross
reaction
domain
sera
well
suit
diagnost
assay
aim
resolv
individu
viru
serotyp
without
recours
revers
transcriptasepolymeras
chain
reaction
rtpcr
viru
neutral
assay
requir
specialist
facil
take
time
note
baculoviru
express
alreadi
use
extens
gener
candid
influenza
vaccin
cox
et
al
nichol
treanor
treanor
et
al
treanor
weldon
et
al
chang
ha
format
requir
allow
hafc
fusion
protein
effect
substitut
nonfus
molecul
would
provid
rapid
immun
respons
smaller
dose
immunogen
without
compromis
spectrum
antibodi
respons
combin
ha
subtyp
modifi
form
hafc
fusion
protein
may
capabl
gener
broadli
cross
reactiv
antibodi
target
fusion
stalk
ha
offer
possibl
long
term
protect
futur
pandem
strain
corti
et
al
ekiert
et
al
sui
et
al
natur
concern
use
human
fc
immun
enhanc
tag
could
break
toler
gener
degre
autoimmun
howev
suitabl
qualiti
control
purif
stage
possibl
seem
small
firstli
intraven
ig
therapi
alreadi
use
treat
number
sever
viral
infect
junin
viru
enria
et
al
also
use
treatment
sever
infect
hung
et
al
secondli
fc
domain
wide
use
clinic
applic
mani
fc
fusion
protein
undergo
clinic
trial
sever
human
diseas
schmidt
exampl
etanercept
approv
prevent
tumor
necrosi
factor
tnf
depend
inflammatori
diseas
alefacept
use
treat
psoriasi
abatacept
approv
treat
rheumatoid
arthriti
romiplostin
approv
therapi
chronic
immun
thrombocytopen
purpura
schmidt
drug
contain
fc
domain
human
antibodi
use
link
effector
protein
use
fc
domain
case
immun
target
provid
signific
extens
halflif
protein
plasma
increas
avid
ligand
fc
mediat
dimer
schmidt
zhang
et
al
mani
treatment
requir
repeat
dose
autoimmun
emerg
signific
issu
suggest
fc
domain
immunogen
right
present
part
fc
fusion
protein
schmidt
express
fc
tag
protein
shown
gener
applic
solut
improv
immun
target
number
viru
bacteri
vaccin
candid
addit
fc
improv
titer
result
serum
without
compromis
spectrum
antibodi
respons
base
widespread
use
fc
tag
therapeut
applic
use
appear
safe
use
fc
fusion
protein
vaccin
candid
anim
human
market
would
therefor
appear
offer
much
term
speed
effici
uniform
manufactur
